

Special Issue

Epigenetics of Pancreatic Cancer 2.0

Message from the Guest Editors

This Special Issue focuses on the role of epigenetics in pancreatic cancer, a dismal disease predicted to be second cause of cancer death by 2030. This aggressive and rapidly disseminated epithelial neoplasm is highly resistant to conventional chemotherapeutic and radiation-based treatments. The past several decades of pancreatic cancer research have yielded a tremendous amount of knowledge about the genetics of tumor cells; however, this knowledge has not translated into significant clinical advances in treatment and prevention. These genetic-based drivers of pancreatic cancer have been well studied in the past three decades, but they do not account for all of the phenotypic and molecular alterations demonstrated by tumor cells. Pancreatic cancer initiation and progression are the result of a heterogeneous and dynamic combination of both genetic and epigenetic mechanisms. With the identification of epigenetic alterations seen in early pancreatic preneoplastic lesions through the development of pancreatic cancer, an inherent complexity is implied in epigenetic changes that occur in parallel to genetic alterations.

Guest Editors

Dr. Martin E. Fernandez-Zapico

Schulze Center for Novel Therapeutics, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA

Dr. Christopher Pin

Division Head and Scientist, Genetics and Development, Children's Health Research Institute Associate Professor, Depts. of Paediatrics, Physiology and Pharmacology, and Oncology Schulich School of Medicine and Dentistry, University of Western Ontario

Deadline for manuscript submissions

closed (31 July 2021)



Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



mdpi.com/si/58698

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)





Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)



About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).